Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Albert, M. L.
Right arrow Articles by Helm-Estabrooks, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Albert, M. L.
Right arrow Articles by Helm-Estabrooks, N.
NEUROLOGY 1988;38:877
© 1988 American Academy of Neurology

Pharmacotherapy for aphasia

Martin L. Albert, MD, David L. Bachman, MD, Alisa Morgan, PhD and Nancy Helm-Estabrooks, ScD

From the Aphasia Research Center, Departments of Neurology and Audiology/Speech Pathology, Boston University Medical School and Boston Veterans Administration Medical Canter, Boston, MA.

Selected features of aphasia may reflect disruption of specific neurotransmitter systems. Pharmacotherapy focused on these aphasic symptoms may improve language performance following stroke. We attempted to restore speech fluency in a patient with long-standing transcortical motor aphasia by treating his symptoms of hesitancy and impaired initiation of speech with bromocriptine. During therapy his language performance improved substantially, due to reduced latency of response, decreased paraphasias, and increased naming ability. After cessation of drug therapy his language returned to baseline.

Address correspondence and reprint requests to Dr. Albert, Boston VA Medical Center, 150 South Huntington Avenue, Boston, MA 02130.

Supported in part by the Veterans Administration Medical Research Service, NIH Program Project #NS06209, and the Seidel Fund for Research on Dementia.

Received July 22, 1987. Accepted for publication in final form October 13, 1987.




This article has been cited by other articles:


Home page
 NeurologyHome page
F. Ashtary, M. Janghorbani, A. Chitsaz, M. Reisi, and A. Bahrami
A randomized, double-blind trial of bromocriptine efficacy in nonfluent aphasia after stroke
Neurology, March 28, 2006; 66(6): 914 - 916.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. L. Berthier, J. Hinojosa, M. d. C. Martin, and I. Fernandez
Open-label study of donepezil in chronic poststroke aphasia
Neurology, April 8, 2003; 60(7): 1218 - 1219.
[Full Text] [PDF]

Home page
 StrokeHome page
J. Kessler, A. Thiel, H. Karbe, and W. D. Heiss
Piracetam Improves Activated Blood Flow and Facilitates Rehabilitation of Poststroke Aphasic Patients
Stroke, September 1, 2000; 31(9): 2112 - 2116.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
M. L. Albert
Treatment of Aphasia
Arch Neurol, November 1, 1998; 55(11): 1417 - 1419.
[Abstract] [Full Text] [PDF]

Home page
 Vasc MedHome page
J. C Grotta
Prevention and management of stroke
Vascular Medicine, March 1, 1991; 2(1): 3 - 17.
[PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1988 by AAN Enterprises, Inc.